Company intelligence / Profile preview
Immune Cell
Chicago, Illinois, United Statesimmcellther.com ↗
- Ownership
- Private
- Employees
- ~2
- Development stage
- Other
01
Overview
Immune Cell Therapy was a private U.S. biotechnology company focused on cancer immunotherapy. Its lead approach was a personalized DNA-based cancer vaccine using semi-allogeneic fibroblasts transfected with autologous tumor-derived DNA, with an initial clinical focus on non-small cell lung cancer and references to breast cancer. Available sources indicate the company reached Phase 1 clinical testing but did not advance to marketed products or NDA approval. The company appears to have become defunct in 2018 after limited clinical activity.
- Therapeutic areas
- Oncology
- Modalities
- VaccineCell therapyDNA vaccine
- Industry
- Biotech
02
Drug pipeline
1 assetBeyond the preview
Go deeper on Immune Cell.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Immune Cell.